Image 1-Ongentys (opicapone) - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

ONGENTYS (opicapone) for the Treatment of Parkinson’s Disease

Image 1-Ongentys (opicapone)
ONGENTYS (opicapone) is indicated as an add-on treatment to levodopa and carbidopa in patients with Parkinson’s disease experiencing “off” episodes. Credit: Neurocrine Biosciences Inc.